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Abstract	
We previously reported successful classification of breast cancer versus benign tissue using the Cole
relaxation frequency measured on tissue excised during breast surgery as part of a study at two
urban hospitals in the U.S. Midwest. Using that health system’s cancer registry, we have discovered
retrospectively that outcomes for patients who participated in the initial study can be classified
correctly in 3 well-differentiated categories: nonrecurrent (NR); recurrent with no metastasis (RNM);
and recurrent with metastasis (RM). As Cole relaxation frequency increases, the classification moves
from NR to RNM and finally to RM. Multivariate analysis showed a significant association of “timecancer-free” for all patients in these recurrent categories, with P-values ranging between 0.0001 to
0.0047. Thus, this follow-up report shows the potential feasibility of using Cole relaxation frequency as
a prognostic parameter in a larger prospective study. (J Patient Cent Res Rev. 2020;7:343-348.)
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C

ancer is a heterogeneous disease with tumors that
can include cells harboring distinct molecular
signatures that respond differently to the same
therapy.1 Breast cancer, in particular, tends to be unique to
the person. Tumor characteristics and clinical biomarkers
such as size, grade, presence of estrogen and progesterone
receptors (ER and PR), and human epidermal growth
factor receptor (HER2/neu) status all have prognostic
value, and some have predictive value. However, there is
uncertainty about the chemotherapy sensitivity of some
ER-positive, HER2-negative patients with breast cancer,
as patients with similar clinical pictures and tumor
characteristics can have different clinical outcomes.2
Genomic assays that measure the expression of several
tumor genes have been developed to inform prognosis and
guide therapeutic decisions,3 but genomic panels tend to
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provide varied results. A specific tumor may stratify to low
risk in one assay and intermediate or high risk in another.
The OPTIMA feasibility trial in the United Kingdom
was designed to validate the use of multiparameter
assays to direct chemotherapy decisions in patients with
axillary node metastases. Oncotype Dx4 was the primary
assay to determine chemotherapy decisions, but 4 other
multiparameter assays also were performed on the tumors.
A “substantial discordance” was demonstrated in the risk
assignments of individual tumors.5 Only 31% of patients
were classified as low/intermediate risk by all 5 panels,
and only 8% were designated as high risk by all 5 assays.
More than 60% of patients were categorized as high risk
by at least 1 test and also low risk by at least 1 test.5 This
is dramatic variation between assays for the same patient
group. Given these limitations in available prognostic and
predictive technologies, research developing alternate
prognostic parameters is needed.
Due to its heterogeneity, cancer has multiple molecular
pathways that result in malignancy. Investigating
malignancy, by determining the effects of increased
disorder at the nanoarchitecture level within cells in
www.aah.org/jpcrr
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malignant tissue, may be very useful if found to be a
universal change. This is what measuring bioelectrical
impedance does. Characterization of the bioelectric
properties of human tissue was made possible by Cole
et al, whose work produced an equivalent circuit to
model biological impedance behavior.6 This equivalent
circuit, embodied in the Cole function, typically models
the spectral data with 4 parameters, including the
Cole relaxation frequency (CRF). We have previously
demonstrated that CRF is a parameter that can distinguish
malignant from benign breast tissue,7,8 with the CRF up
to 1000 times greater in malignant than in benign tissue.
The objective of this retrospective follow-up study is to
determine if there is a correlation between CRF values
measured at the time of surgery to long-term outcomes for
these patients, using data available in the cancer registry
of a large Midwestern health system. Our hypothesis
with this study is that the higher the CRF value, the more
aggressive the cancer or the more likely it is that the
cancer will recur.

METHODS

Study Design

This retrospective study, approved by the relevant
institutional review board, follows up on a previous
study’s patient cohort for which data were collected from
2003 to 2012.7 That study included consented patients
undergoing excision of a breast abnormality, benign or
malignant. For this retrospective study, only patients
with malignancies who had follow-up clinical visits
available in the cancer registry maintained by Aurora
Health Care (Milwaukee, WI) were included (108 of 187
study participants). Of these 108 patients, 84 did not have
cancer recur and 24 had recurrence (7 with metastasis).
All information regarding study design follows that
provided in the published report.7
Analysis Methods

The scientific notation for CRF (typically ranging
from 1×105 Hz to 2×106 Hz for cancer specimens) is
cumbersome, so a dimensionless number was created by
dividing (ie, normalizing) the CRF by the lowest value
indicative of cancer, 1×105 Hz, to yield values from
1 to 20. We termed this dimensionless parameter the
“normalized Cole relaxation frequency” or nCRF. This
prespecified range of nCRF values was chosen to include
all data for cancerous lesions found in this patient cohort.
Several histologic prognostic indicators were considered
for comparison to nCRF. These included the Nottingham
Prognostic Index (NPI),9 NPI Plus,10 and tumor grade.11,12
Data available from the Aurora Cancer Registry allowed
the computation of NPI, a combination of tumor size, node
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status, and grade. This produced a scale ranging from 2 to
8; the higher the scale number, the worse the prognosis.
nCRF score ranges from 1 to 20, thus a comparison to NPI
was possible. NPI Plus includes similar clinicopathologic
variables as NPI but additionally includes tumor biology
such as luminal classes (luminal A, N, and B), basal
classes (basal p53 altered and basal p53 normal), and
HER2-positive classes (HER2+/ER+ and HER2+/ER-).13
Grade is reported in two ways — 1) calculated from a
combination of tubule formation, nuclear polymorphism,
and mitotic counts reported on a scale of 1 to 9; and 2)
in 3 steps as grade I (well-differentiated, score 3–5),
grade II (moderately differentiated, score 6–7), and
grade III (poorly differentiated, score 8–9). The 3-step
differentiation score was the only information available
from the cancer registry. Since the Aurora Cancer
Registry reported only the differentiation results for
grade and not the 1–9 scores directly, and information
regarding luminal and basal classes were not available, it
was not possible to make a similar comparison of grade
and NPI Plus respective to nCRF, as could be done with
NPI. However, it was possible to include grade in the
multivariate analysis.
In this work only, NPI was compared to nCRF using
exceedance averaging, and both NPI and grade were
compared using multivariate analysis to investigate
performance of other histology-derived parameters in
this patient cohort. Adjusted Cox proportional hazards
models were used to determine the effect of nCRF versus
NPI, as well as nCRF versus grade, on the length of
time after surgery that patients remained cancer-free (ie,
“time-cancer-free”). Models were adjusted for age, ER,
PR, and HER2/neu status. Hazard ratios (HR) and 95%
confidence intervals were reported. Statistical models
were performed in SAS 9.4 software (SAS Institute Inc.).
Likelihood ratios14 (referred to hereafter as L) were
used to compare the probability of one outcome versus
another on the basis of nCRF values and, thus, were used
to predict the diagnostic power of nCRF.
To allow comparison of nCRF to patient outcomes, the
cancer registry supplied the number of days a patient
was cancer free after surgery or, occasionally, “never
cancer free” (eg, stage IV) based on follow-up clinic
visits. The overall average time of follow-up was 8.2
years. To minimize the effects of missing time-cancerfree data (censored), an exceedance average was used to
analyze the data.15 This average weighted the measured
time-cancer-free by 0 (zero) for nCRF values less than
a chosen value and by 1 above that value. This average
answered the question: What is the expectation of an
average time-cancer-free going forward from the chosen
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value of nCRF? Note that this is different from the
overall average, which weights all data by 1.

RESULTS

Figure 1 is a comparison of the likelihood of recurrence
without metastasis (RNM to nonrecurrence (NR), or
L(RNM:NR), and likelihood of recurrence with metastasis
(RM) compared to NR, or L(RM:NR), plotted against
nCRF. Note that these two groups correspond to two
different regions of nCRF values that are contiguous with
very little overlap. In nCRF range 3–6, the L(RNM:NR)
dominates. When nCRF exceeds 6, the L(RM:NR)
dominates and increases dramatically as the nCRF rises.
This result can be expressed as follows: below nCRF of
3, there were no recurrent cases; in nCRF of 3 to 6, there
was recurrence without metastasis; above nCRF of 6,
there is recurrence with metastasis.
Figure 2 illustrates a second independent statistical
technique for determining the correlation of the groupings
NR, RNM, and RM. This is the aforementioned
exceedance averaging technique. The green curve is the
exceedance average for the nCRF measurements. This
figure also shows how the exceedance average for the
NPI compares to the nCRF exceedance average. The first
distinction between these two curves is that the NPI curve
has no sharp demarcations between regions. In fact, below
the graph in Figure 2 are some statistical comparisons

between specific NPI regions and nCRF regions. Whereas
the nCRF regions have very small comparative P-values
(indicating that they are statistically different), the NPI
regions NPI-1 and NPI-2 are statistically the same and
only region NPI-3 is statistically independent. One can
see this graphically in the curve by noting that NPI-1 and
NPI-2 fit very well to a straight line while the NPI-3 region
bows above that line and is clearly different in the figure.
This result means that NPI only distinguishes between
metastatic cases and does not further distinguish between
nonrecurrence and recurrence with no metastasis. On the
other hand, all three regions of nCRF (ie, NR, RNM, and
RM) are clearly statistically significantly different.
Multivariate analysis of time-cancer-free showed
nCRF was the only parameter to consistently yield
correct prognoses for all recurrences, with or without
metastasis (Table 1). Adjusting for NPI, age, ER, PR,
and HER2/neu, nCRF was significantly associated with
higher time-cancer-free among those with combined
recurrence (HR: 1.08; P=0.0095) and those with
metastatic recurrence (HR: 1.18; P=0.0003). HR was
proportionally constant over time, and HR for relevant
variables was independent of time. Adjusting for grade,
age, ER, PR, and HER2/neu, nCRF was significantly
associated with time-cancer-free among those with
combined recurrences (HR: 1.083; P=0.0047) and those
with metastatic recurrence (HR: 1.185; P=0.0001).

No recurrent
data in this
region

Figure 1. Likelihood regions obtained from a quadratic fit of likelihood (L) data vs normalized Cole relaxation
frequency (nCRF). Three regions are identified: no recurrence (L-NR) with nCRF of <3; recurrence with no
metastasis (L-RNM) with nCRF of 3–6; recurrence with metastasis (L-RM) with nCRF of >6. The standard error
bars for the L-RNM region (plotted in blue) are very small compared to the L-RM region (plotted in red) due to a
smaller number of data points in the L-RM region.
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Figure 2. This plot compares
exceedance averaged timecancer-free for normalized Cole
relaxation frequency (nCRF, in
green) and Nottingham Prognostic
Index (NPI, in red). The prognosis
for time-cancer-free (years) is
plotted on the vertical axis. The
slope of the nCRF plot changes
abruptly at two region boundaries
— where L-NR changes to
L-RNM and where L-RNM
changes to L-RM. NPI plots do
not have similar demarcations at
the boundary of regions NPI-1
to NPI-2, but there is a change
of slope at NPI-2 to NPI-3.
The t-test for independence
for these regions is displayed
below the figure and shows
that NPI is only a prognostic
parameter for recurrence
with metastasis, while nCRF
distinguishes all regions, one from
the other, allowing statistically
significant discrimination of no
recurrence (NR), recurrence
with no metastasis (RNM), and
recurrence with metastasis (RM).

DISCUSSION

This study found a strong correlation between breast
cancer nCRF values obtained at the time of surgery and
patients’ outcomes of recurrence or time-cancer-free. We
found that when nCRF is less than 3, it is likely that the
sample, while originally malignant, will not recur. When
nCRF is in the range of 3 to 6, it is likely that the cancer
will recur but will not metastasize. However, when
nCRF is greater than 6, there is an increasingly greater
likelihood that the cancer will recur and will metastasize.
Multivariate analysis (Table 1) also confirms these
conclusions. A larger prospective trial will be needed
to compare nCRF and patient outcomes against a more
inclusive prognostic group, such as luminal, basal, and
HER2/neu subgroups, as is used in NPI Plus.
Our findings are not surprising because bioelectrical
impedance appears to measure changes in cells, as they
progress from benign to malignant, that are not always
discernible by histology. A higher nCRF value may reflect
a more extensive change and risk of an aggressive cancer
that is prone to recur or metastasize. One theoretical
explanation for this is that as cells transform from benign
to malignant, they are increasingly disorganized, based
on partial wave optical scattering data for cells from the
colon, pancreas, and lung.16 This disorganization causes
346 JPCRR • Volume 7, Issue 4 • Fall 2020

electrical polarization of cell contents to decrease, which
then results in an increase in the relaxation frequency.7
Further, based on the field carcinogenesis model,17 this
may well be a universal property of cells as they transform
regardless of organ of origin of the cell. Evidence of
disorganization and/or increased relaxation frequencies has
been reported for different cell types besides breast tissue,
including colon, pancreas, lung,16 and nonmelanoma skin
cancer.18 Therefore, we hypothesize that nCRF measures
a universal characteristic of cancer and malignancy
that correlates with the degree that a field of cells has
transformed from benign to cancerous. nCRF could be of
significant generalized importance for cancer diagnosis
and treatment, as it appears to be agnostic of cancer type.
Our observations demonstrate that nCRF values
correlate well with breast cancer outcomes of recurrence,
metastasis, and time-cancer-free. Multivariate analysis
shows nCRF values are statistically significant in contrast
to many other prognostic parameters in use today. nCRF
is a potentially clinically useful prognostic parameter
for breast cancer. This is a small retrospective feasibility
study and must be validated in a larger prospective
trial that compares nCRF values with other prognostic
parameters and tumor genetic markers.
Brief Report

Negative
Negative
Negative
Negative

ER, estrogen receptor; HER2, human epidermal growth factor receptor; nCRF, normalized Cole relaxation frequency; NPI, Nottingham Prognostic Index;
PR, progesterone receptor; Ref., Reference.

Negative
Negative
Negative
Negative

0.81810
0.00010
0.15180
0.73510
0.04880
0.26870
0.97810
0.528, 1.656
1.088, 1.29
0.991, 1.058
0.154, 3.746
1.007, 16.288
0.388, 29.985
0.41, 2.499
0.935
1.185
1.024
0.759
4.051
1.013
3.41
Grade
nCRF
Age
ER
PR
HER2+
HER2 equivocal
0.43450
0.00470
0.24760
0.42650
0.18050
0.54760
0.62830
1.134
1.083
1.01
0.655
1.914
0.863
0.712
Grade
nCRF
Age
ER
PR
HER2+
HER2 equivocal

Negative
Negative
Negative
Negative

0.827, 1.556
1.025, 1.144
0.993, 1.028
0.231, 1.859
0.74, 4.947
0.235, 2.154
0.475, 1.567

Negative
Negative
Negative
Negative

P

0.44530
0.00030
0.10200
0.87260
0.06000
0.22330
0.97420
0.84, 1.51
1.08, 1.29
1, 1.06
0.22, 5.88
0.07, 1.06
0.45, 31.86
0.41, 2.52
1.12
1.18
1.03
1.14
0.27
3.77
1.02
NPI
nCRF
Age
ER
PR
HER2+
HER2 equivocal
NPI
nCRF
Age
ER
PR
HER2+
HER2 equivocal

1.14
1.08
1.01
1.48
0.53
0.8
1.2

0.97, 1.33
1.02, 1.14
0.99, 1.03
0.53, 4.19
0.21, 1.38
0.3, 2.14
0.66, 2.17

0.10750
0.0095
0.22480
0.45650
0.19420
0.65400
0.55610

95% CI limits
(lower, upper)
Hazard
ratio
Ref.
category
Prognostic
parameter
Hazard
ratio
Prognostic
parameter

Ref.
category

95% CI limits
(lower, upper)

P

Metastatic cancer recurrence
Combined nonmetastatic and metastatic cancer recurrence

Table 1. Multivariate Cox Proportional Hazards Analysis Results for Prognosis of Recurrence
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Patient-Friendly Recap
• Breast cancer treatment is difficult to predict,
as patients with similar clinical and tumor
characteristics can have vastly different
clinical outcomes. More reliable measures
are needed to know which patients may
benefit from specific therapies.
• The authors studied how electrical current
interacts with tissue and derived a parameter
called the Cole relaxation frequency to test
the feasibility of using this frequency to
predict the likelihood a patient’s cancer will
recur following treatment.
• They found that a Cole relaxation frequency
level higher than 6 resulted in significantly
more patients recurring with metastatic
cancer. More research is needed to validate
this biomarker as prognostic for breast cancer.
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